HCAT on Nasdaq
Health Catalyst, Inc.
In its 2026 annual report the company says: “We are a leading provider of data and analytics technology and services to healthcare organizations. Our Solution comprises our cloud-based data and analytics platform, software applications, and expertise. Our clients, which are primarily healthcare providers, use our Solution to manage their data, derive analytical insights to operate their organization, and produce measurable clinical, financial, and operational improvements.”5 It is headquartered in South Jordan, United States.2 Its shares trade on Nasdaq under the symbol HCAT.2
Price unavailable
Last updated Oct 21, 2026.
Overview
Compare with HEALTHSTREAM INC, Eventbrite or Yalla Group Ltd, or pick any stock.
- TickerHCAT on Nasdaq2
- IndustryServices-Computer Programming, Data Processing, Etc.2
- HeadquartersSouth Jordan, United States2
- Incorporated inDE3
- Business address10897 South River Front Parkway, #300, South Jordan, Ut 840953
- Filer categoryAccelerated filer3
- Legal formCorporation2
- LEI549300223PL6GWKVJG922
- StatusActive2
- LEI statusIssued and current2
- Registered addressC/O THE CORPORATION TRUST COMPANY, 19801 Wilmington, United States2
- Registered withDivision of Corporations, Department of State, 50402212
See how the biggest companies compare on our leaderboards
We are a leading provider of data and analytics technology and services to healthcare organizations. Our Solution comprises our cloud-based data and analytics platform, software applications, and expertise. Our clients, which are primarily healthcare providers, use our Solution to manage their data, derive analytical insights to operate their organization, and produce measurable clinical, financial, and operational improvements. We envision a future where all healthcare decisions are data-informed.5 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-51.7%Operating margin6
-57.2%Net margin6
1.5%Revenue growth, 20256
-72.4%Return on equity6
0.62×Debt to equity6
-$237.0KFree cash flow6
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Recurring Technology brought in 40% of the revenue Health Catalyst, Inc. broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Recurring Technology | $187.2M | $194.9M | $208.3M |
| Technology | $187.6M | $194.9M | $208.3M |
| Professional Services | $108.4M | $111.7M | $102.9M |
Business segments
Technology brought in 67% of the revenue Health Catalyst, Inc. broke down this way in fiscal 2025.
Business segments by year
| Business segments | 2023 | 2024 | 2025 |
|---|---|---|---|
| Technology | $187.6M | $194.9M | $208.3M |
| Professional Services | $108.4M | $111.7M | $102.9M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development16¢$49.8M
- Other costs84¢$260.6M
- Income tax0¢$716.0K
Out of $311.1M in revenue.6 The company lost money this year.
Where each dollar of operating cash went, fiscal 2025
- Capital spending16¢$968.0K
- Share buybacks84¢$5.0M
Out of $731.0K of cash from operations. Spending exceeded cash from operations; the rest came from savings or borrowing.6
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Revenue | $311.1M | $306.6M | $295.9M |
| Total cost of revenue, excluding depreciation and amortization | $159.5M | $165.8M | $164.1M |
| Sales and marketing | $52.5M | $54.4M | $67.3M |
| Research and development | $49.8M | $58.0M | $72.6M |
| General and administrative | $49.6M | $56.8M | $76.6M |
| Depreciation and amortization | $50.5M | $41.4M | $42.2M |
| Impairment of goodwill and intangible assets | $110.2M | $0 | $0 |
| Total operating expenses | $312.5M | $210.6M | $258.7M |
| Loss from operations | -$160.9M | -$69.8M | -$126.9M |
| Interest and other (expense) income, net | -$16.4M | $637.0K | $9.1M |
| Loss before income taxes | -$177.3M | -$69.2M | -$117.8M |
| Income tax provision | $716.0K | $333.0K | $356.0K |
| Net loss | -$178.0M | -$69.5M | -$118.1M |
| Net loss per share, basic (in USD per share) | -$2.55 | -$1.15 | -$2.09 |
| Net loss per share, diluted (in USD per share) | -$2.55 | -$1.15 | -$2.09 |
| Weighted-average shares outstanding used in calculating net loss per share, basic (in shares) | 69.9M shares | 60.2M shares | 56.4M shares |
| Weighted-average shares outstanding used in calculating net loss per share, diluted (in shares) | 69.9M shares | 60.2M shares | 56.4M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $50.8M | $249.6M | ||
| Short-term investments | $44.9M | $142.4M | ||
| Accounts receivable, net | $59.1M | $57.2M | ||
| Prepaid expenses and other assets | $14.4M | $16.5M | ||
| Total current assets | $169.3M | $465.6M | ||
| Property and equipment, net | $33.8M | $29.4M | ||
| Intangible assets, net | $77.7M | $86.1M | ||
| Operating lease right-of-use assets | $6.6M | $12.1M | ||
| Goodwill | $209.1M | $259.8M | $190.7M | |
| Other assets | $6.1M | $6.0M | ||
| Total assets | $502.6M | $858.9M | ||
| Accounts payable | $9.4M | $11.4M | ||
| Accrued liabilities | $18.7M | $26.3M | ||
| Deferred revenue | $56.1M | $53.3M | ||
| Operating lease liabilities | $3.8M | $3.6M | ||
| Current portion of long-term debt | $1.6M | $231.2M | ||
| Total current liabilities | $89.6M | $325.9M | ||
| Long-term debt, net of current portion | $151.6M | $151.2M | ||
| Deferred revenue, net of current portion | $410.0K | $249.0K | ||
| Operating lease liabilities, net of current portion | $14.2M | $16.3M | ||
| Contingent consideration liabilities, net of current portion | $250.0K | $0 | ||
| Other liabilities | $798.0K | $154.0K | ||
| Total liabilities | $256.9M | $493.7M | ||
| Preferred stock, $0.001 par value per share; 25,000,000 shares authorized and no shares issued and outstanding as of December 31, 2025 and 2024 | $0 | $0 | ||
| Common stock, $0.001 par value per share, and additional paid-in capital; 500,000,000 shares authorized as of December 31, 2025 and 2024; 72,027,332 and 64,043,799 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $1.6B | $1.6B | ||
| Accumulated deficit | -$1.4B | -$1.2B | ||
| Accumulated other comprehensive income (loss) | $1.6M | -$835.0K | ||
| Total stockholders equity | $245.8M | $365.2M | $366.9M | $425.0M |
| Total liabilities and stockholders equity | $502.6M | $858.9M | ||
| Preferred stock, par value (in USD per share) | $0.00 | $0.00 | ||
| Preferred stock, shares authorized (in shares) | 25.0M shares | 25.0M shares | ||
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | ||
| Common stock, par value (in USD per share) | $0.00 | $0.00 | ||
| Common stock, shares authorized (in shares) | 500.0M shares | 500.0M shares | ||
| Common stock, shares issued (in shares) | 72.0M shares | 64.0M shares | ||
| Common stock, shares, outstanding (in shares) | 72.0M shares | 64.0M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $50.8M | $249.6M | ||
| Short-term investments | $44.9M | $142.4M | ||
| Accounts receivable, net | $59.1M | $57.2M | ||
| Prepaid expenses and other assets | $14.4M | $16.5M | ||
| Total current assets | $169.3M | $465.6M | ||
| Property and equipment, net | $33.8M | $29.4M | ||
| Intangible assets, net | $77.7M | $86.1M | ||
| Operating lease right-of-use assets | $6.6M | $12.1M | ||
| Goodwill | $209.1M | $259.8M | $190.7M | |
| Other assets | $6.1M | $6.0M | ||
| Total assets | $502.6M | $858.9M | ||
| Accounts payable | $9.4M | $11.4M | ||
| Accrued liabilities | $18.7M | $26.3M | ||
| Deferred revenue | $56.1M | $53.3M | ||
| Operating lease liabilities | $3.8M | $3.6M | ||
| Current portion of long-term debt | $1.6M | $231.2M | ||
| Total current liabilities | $89.6M | $325.9M | ||
| Long-term debt, net of current portion | $151.6M | $151.2M | ||
| Deferred revenue, net of current portion | $410.0K | $249.0K | ||
| Operating lease liabilities, net of current portion | $14.2M | $16.3M | ||
| Contingent consideration liabilities, net of current portion | $250.0K | $0 | ||
| Other liabilities | $798.0K | $154.0K | ||
| Total liabilities | $256.9M | $493.7M | ||
| Preferred stock, $0.001 par value per share; 25,000,000 shares authorized and no shares issued and outstanding as of December 31, 2025 and 2024 | $0 | $0 | ||
| Common stock, $0.001 par value per share, and additional paid-in capital; 500,000,000 shares authorized as of December 31, 2025 and 2024; 72,027,332 and 64,043,799 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $1.6B | $1.6B | ||
| Accumulated deficit | -$1.4B | -$1.2B | ||
| Accumulated other comprehensive income (loss) | $1.6M | -$835.0K | ||
| Total stockholders equity | $245.8M | $365.2M | $366.9M | $425.0M |
| Total liabilities and stockholders equity | $502.6M | $858.9M | ||
| Preferred stock, par value (in USD per share) | $0.00 | $0.00 | ||
| Preferred stock, shares authorized (in shares) | 25.0M shares | 25.0M shares | ||
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | ||
| Common stock, par value (in USD per share) | $0.00 | $0.00 | ||
| Common stock, shares authorized (in shares) | 500.0M shares | 500.0M shares | ||
| Common stock, shares issued (in shares) | 72.0M shares | 64.0M shares | ||
| Common stock, shares, outstanding (in shares) | 72.0M shares | 64.0M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$178.0M | -$69.5M | -$118.1M |
| Stock-based compensation expense | $27.0M | $40.1M | $55.8M |
| Depreciation and amortization | $50.5M | $41.4M | $42.2M |
| Investment discount and premium accretion | -$1.6M | -$4.8M | -$9.7M |
| Impairment of long-lived assets | $6.9M | $2.2M | $4.1M |
| Non-cash operating lease expense | $2.9M | $2.7M | $3.0M |
| Provision for expected credit losses | $1.5M | $1.2M | $1.8M |
| Amortization of debt discount, issuance costs, and deferred financing costs | $3.7M | $3.3M | $1.5M |
| Deferred tax provision | $81.0K | $77.0K | $8.0K |
| Change in fair value of contingent consideration liabilities | -$7.1M | -$1.6M | $0 |
| Impairment of goodwill and intangible assets | $110.2M | $0 | $0 |
| Other | -$429.0K | $141.0K | $67.0K |
| Accounts receivable, net | -$1.8M | $4.3M | -$13.7M |
| Prepaid expenses and other assets | $1.6M | -$50.0K | $164.0K |
| Accounts payable, accrued liabilities, and other liabilities | -$11.5M | $5.6M | $4.9M |
| Deferred revenue | $607.0K | -$7.0M | -$1.5M |
| Operating lease liabilities | -$4.0M | -$3.5M | -$3.6M |
| Net cash provided by (used in) operating activities | $731.0K | $14.6M | -$33.1M |
| Proceeds from the sale and maturity of short-term investments | $163.9M | $242.1M | $336.8M |
| Purchases of short-term investments | -$65.1M | -$168.3M | -$290.8M |
| Capitalization of internal-use software | -$19.8M | -$14.3M | -$12.0M |
| Acquisition of businesses, net of cash acquired | -$41.1M | -$80.3M | -$11.4M |
| Purchases of property and equipment | -$968.0K | -$1.6M | -$1.2M |
| Purchases of intangible assets | -$805.0K | -$508.0K | -$1.1M |
| Proceeds from the sale of property and equipment | $44.0K | $13.0K | $31.0K |
| Net cash provided by (used in) investing activities | $36.2M | -$22.9M | $20.3M |
| Proceeds from issuance of long-term debt, net of issuance costs | $0 | $152.3M | $0 |
| Payment of deferred financing costs | $0 | -$2.2M | $0 |
| Repayment of debt | $232.3M | $959.0K | $0 |
| Proceeds from employee stock purchase plan | $1.5M | $2.4M | $3.6M |
| Proceeds from exercise of stock options | $0 | $169.0K | $950.0K |
| Repurchase of common stock | -$5.0M | $0 | -$1.8M |
| Net cash (used in) provided by financing activities | -$235.8M | $151.7M | $2.7M |
| Effect of exchange rate changes on cash and cash equivalents | $27.0K | -$34.0K | $21.0K |
| Net (decrease) increase in cash and cash equivalents | -$198.8M | $143.4M | -$10.0M |
| Cash paid for interest | $21.9M | $10.1M | $5.8M |
| Common stock issued in connection with business acquisitions | $31.6M | $24.9M | $0 |
| Operating lease right-of-use assets obtained in exchange for operating lease obligations | $806.0K | $1.3M | $2.0M |
| Stock-based compensation capitalized as internal-use software | $1.0M | $1.0M | $889.0K |
| Capitalized internal-use software included in accounts payable and accrued liabilities | $189.0K | $265.0K | $169.0K |
| Purchase of property and equipment included in accounts payable and accrued liabilities | $76.0K | $13.0K | $7.0K |
| Purchase of intangible assets included in accounts payable and accrued liabilities | $1.7M | $0 | $1.3M |
No quarter-by-quarter statement was filed.
Corporate structure
Health Catalyst, Inc. sits at the top of its group. 19 entities, 5 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Health Catalyst, Inc.
- Palogic Value Management, L.P. Filed SCHEDULE 13D/A on Health Catalyst, Inc., latest Sep 8, 2026 (2 filings since Jun 22, 2026)
- Stoney Lonesome HF LP Filed SCHEDULE 13G/A on Health Catalyst, Inc., latest Aug 14, 2026 (3 filings since Dec 22, 2025)
- BlackRock Filed SCHEDULE 13G/A on Health Catalyst, Inc., latest Jul 28, 2026 (5 filings since Feb 3, 2022)
- Impax Asset Management Group Filed SCHEDULE 13G on Health Catalyst, Inc., latest Jul 21, 2026
- Whetstone Capital Advisors, LLC Filed SCHEDULE 13D/A on Health Catalyst, Inc., latest Jun 8, 2026 (5 filings since Sep 8, 2025)
- VANGUARD GROUP INC Filed SCHEDULE 13G/A on Health Catalyst, Inc., latest Mar 27, 2026 (8 filings since Feb 10, 2022)
- First Light Asset Management, LLC Filed SCHEDULE 13D/A on Health Catalyst, Inc., latest Mar 13, 2026 (6 filings since Nov 14, 2024)
- Point72 Asset Management, L.P. Filed SC 13G/A on Health Catalyst, Inc., latest Nov 14, 2024 (5 filings since Nov 3, 2022)
- Wellington Management Company Filed SC 13G/A on Health Catalyst, Inc., latest Nov 8, 2024 (4 filings since Feb 4, 2022)
- AllianceBernstein Filed SC 13G/A on Health Catalyst, Inc., latest Feb 14, 2023 (2 filings since Feb 14, 2022)
- Capital Research Global Investors Filed SC 13G/A on Health Catalyst, Inc., latest Feb 13, 2023 (2 filings since Feb 11, 2022)
- MILLENNIUM MANAGEMENT LLC Filed SC 13G/A on Health Catalyst, Inc., latest Jan 13, 2023 (2 filings since Aug 30, 2022)
- Health Catalyst, Inc. South Jordan, Utah, United States
- Able Health, LLC Subsidiary · Delaware, United States
- ARMUS I LLC Subsidiary · Delaware, United States
- Carevive Systems, LLC Subsidiary · Delaware, United States
- Electronic Registry Systems, LLC Subsidiary · Delaware, United States
- Health Catalyst Australia PTY LTD Subsidiary · Australia
- Health Catalyst India Private Limited Subsidiary · India
- Health Catalyst Singapore Pte. Ltd. Subsidiary · Singapore
- Health Catalyst UK Ltd Subsidiary · United Kingdom
- Healthfinch, LLC Subsidiary · Delaware, United States
- Intraprise Health, LLC Subsidiary · Delaware, United States
- KPI Ninja, LLC Subsidiary · Delaware, United States
- Lumeon Ltd Subsidiary · United Kingdom
- Medicity LLC Subsidiary · Delaware, United States
- PatientBond India Private Limited Subsidiary · India
- Psynteractive LLC Subsidiary · Delaware, United States
- Twistle, LLC Subsidiary · Delaware, United States
- Upfront Healthcare Services, LLC Subsidiary · Delaware, United States
- Vitalware, LLC Subsidiary · Delaware, United States
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Health Catalyst, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $87.2M6 Dec 31, 2025 | $68.8M6 Dec 31, 2024 | +26.7% |
| Accumulated depreciation | $53.3M6 Dec 31, 2025 | $39.4M6 Dec 31, 2024 | +35.4% |
| Property and equipment, net | $33.8M6 Dec 31, 2025 | $29.4M6 Dec 31, 2024 | +15.1% |
| Operating-lease assets (leased space) | $6.6M6 Dec 31, 2025 | $12.1M6 Dec 31, 2024 | −44.9% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $50.8M6 Dec 31, 2025 | $249.6M6 Dec 31, 2024 | −79.6% |
| Marketable securities, current | $44.9M6 Dec 31, 2025 | $142.4M6 Dec 31, 2024 | −68.4% |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Goodwill | $209.1M6 Dec 31, 2025 | $259.8M6 Dec 31, 2024 | −19.5% |
| Intangible assets, net (excluding goodwill) | $77.7M6 Dec 31, 2025 | $86.1M6 Dec 31, 2024 | −9.7% |
| Finite-lived intangibles, gross | $275.9M6 Dec 31, 2025 | $248.8M6 Dec 31, 2024 | +10.9% |
| Accumulated amortization | $198.2M6 Dec 31, 2025 | $162.7M6 Dec 31, 2024 | +21.8% |
| Finite-lived intangibles, net | $77.7M6 Dec 31, 2025 | $86.1M6 Dec 31, 2024 | −9.7% |
Properties, in its own words
Our principal executive offices are located in South Jordan, Utah where we lease facilities totaling approximately 128,037 square feet under a lease agreement that expires on December 31, 2031, of which 88,164 square feet is currently subleased. We use this facility for administration, sales and marketing, technology and development, and professional services. We also lease offices elsewhere for sales, research and development, professional services, and other personnel, including offices in Minneapolis, Minnesota and Hyderabad, India.
We believe that our facilities are adequate to meet our needs for the immediate future, and that, should it be needed, suitable additional space will be available to accommodate any such expansion of our operations.
Item 2 of the 10-K filed Mar 12, 2026.5
Leadership
Who has led Health Catalyst, Inc., and when. Pick a name to see everywhere that person has worked.
Chief financial officer
Chief operating officer
20202025
- Chief executive officerBenjamin Albert Feb 27, 2026 to Sep 16, 202614
- Chief executive officerSimeon Kohl Sep 16, 2026 to now15
- Chief executive officerDaniel D. Burton Jul 24, 2019 to Feb 27, 202616
- PresidentBenjamin Albert Sep 26, 2025 to now17
- PresidentJames Patrick Nelli Jr. Feb 22, 2021 to Sep 6, 202218
- Chief financial officerJason Alger Mar 5, 2024 to now19
- Chief financial officerBryan Truman Hunt Jan 11, 2021 to Mar 5, 202420
- Chief financial officerJames Patrick Nelli Jr. Jul 24, 2019 to Dec 17, 202021
- Chief operating officerBenjamin Albert Sep 26, 2025 to now17
- Chief operating officerDaniel Lesueur Mar 5, 2024 to Sep 26, 202522
- Chief operating officerAnne Marie Bickmore Apr 13, 2023 to Dec 5, 202323
- Chief operating officerDale Sanders Jul 24, 2019 to Jul 24, 201924
- Chief operating officerPaul Horstmeier Jul 24, 2019 to Mar 24, 202325
Board members and other officers (26)
- Chief Growth OfficerKevin Lee Freeman Sep 12, 2022 to now26
- Chief Accounting OfficerJason Alger Jan 11, 2021 to Feb 22, 202427
- Chief Technology OfficerBryan Richard Hinton Apr 8, 2021 to Sep 6, 202228
- Chief Technology OfficerDale Sanders Jan 2, 2020 to Sep 3, 202029
- Chief People OfficerLinda Llewelyn Jul 24, 2019 to now30
- Board memberBenjamin Albert Feb 27, 2026 to now14
- Board memberSteven H. Nelson May 4, 2026 to now31
- Board memberSimeon Kohl Sep 16, 2026 to now15
- Board memberJustin Spencer Sep 3, 2025 to now32
- Board memberMathew Paul Arens Dec 3, 2025 to now33
- Board memberGreen Jill Hoggard Dec 4, 2024 to now34
- Board memberMatthew Kolb Jul 11, 2023 to Jul 11, 202335
- Board memberDawn Smith Jan 2, 2020 to now36
- Board memberJulie Larson-Green Jan 2, 2020 to now37
- Board memberMark B. Templeton Jun 17, 2020 to Jun 16, 202338
- Board memberAnita Pramoda Jul 24, 2019 to Dec 3, 202439
- Board memberD. Fraser Bullock Jul 24, 2019 to Jun 14, 202140
- Board memberDaniel D. Burton Jul 24, 2019 to now16
- Board memberDuncan Gallagher Jul 24, 2019 to now41
- Board memberJohn A. Kane Jul 24, 2019 to now42
- Board memberMichael Edward Dixon Jul 24, 2019 to Jun 17, 202043
- Board memberPromod Haque Jul 24, 2019 to Jan 23, 202044
- Board memberTimothy G. Ferris Jul 24, 2019 to Jan 13, 202145
- Board memberTodd C. Cozzens Jul 24, 2019 to Jun 17, 202046
- General counselBenjamin Landry May 4, 2023 to now47
- General counselDaniel H. Orenstein Jul 24, 2019 to Mar 3, 202348
Named in SEC Form D filings
People the company listed in its private-offering notices.
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
- ARMUS I LLC Delaware, United States4
- Able Health, LLC Delaware, United States4
- Carevive Systems, LLC Delaware, United States4
- Electronic Registry Systems, LLC Delaware, United States4
- Health Catalyst Australia PTY LTD Australia4
- Health Catalyst India Private Limited India4
- Health Catalyst Singapore Pte. Ltd. Singapore4
- Health Catalyst UK Ltd England and Wales4
- Healthfinch, LLC Delaware, United States4
- Intraprise Health, LLC Delaware, United States4
- KPI Ninja, LLC Delaware, United States4
- Lumeon Ltd England and Wales4
- Lumeon, LLC Delaware, United States4
- Medicity LLC Delaware, United States4
- PatientBond India Private Limited India4
- Psynteractive LLC Delaware, United States4
- Twistle, LLC Delaware, United States4
- Upfront Healthcare Services, LLC Delaware, United States4
- Vitalware, LLC Delaware, United States4
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Former names
- HQC Holdings, Inc.Mar 27, 2015 to Feb 19, 20163
Timeline
- Sep 16, 2026New chief executive Simeon Kohl becomes CEO15
- Sep 14, 20268-K Executive or director change; Regulation FD disclosure51
- Sep 8, 20268-K Executive or director change; Regulation FD disclosure52
- Aug 6, 20268-K Ended a material agreement; Completed an acquisition or sale; Results of operations53
- Jul 20, 20268-K Shareholder vote54
- Jun 4, 20268-K Entered a material agreement; Regulation FD disclosure55
- May 11, 20268-K Results of operations56
- Apr 30, 20268-K Executive or director change; Regulation FD disclosure57
- Apr 27, 20268-K Executive or director change; Other events58
- Apr 3, 20268-K Executive or director change59
- Mar 12, 20268-K Results of operations60
- Feb 27, 2026New chief executive Benjamin Albert becomes CEO14
- Feb 18, 20268-K Executive or director change; Regulation FD disclosure61
- Jan 23, 20268-K Executive or director change62
- Jul 24, 2019New chief executive Daniel D. Burton becomes CEO16
- Sep 20, 2011Founded Health Catalyst, Inc. is founded2
Calendar
Coming up
- Nov 9, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.04) a share, on Nov 10, 2025.63
When it reported results
- Aug 6, 2026Reported quarterly or annual results53
- May 11, 2026Reported quarterly or annual results56
- Mar 12, 2026Reported quarterly or annual results60
- Jan 12, 2026Reported quarterly or annual results64
- Nov 10, 2025Reported quarterly or annual results65
- Aug 7, 2025Reported quarterly or annual results66
- May 7, 2025Reported quarterly or annual results67
- Feb 26, 2025Reported quarterly or annual results68
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
628 filings to the SEC since October 2021: 8 annual reports, 15 quarterly reports, 48 major events, 334 insider forms, 48 large holders, 6 private raises, 169 other. The latest 20:
- Oct 5, 20264 PRIMARY DOCUMENT EDGAR
- Oct 5, 20263 PRIMARY DOCUMENT EDGAR
- Sep 16, 20264 PRIMARY DOCUMENT EDGAR
- Sep 16, 20263 PRIMARY DOCUMENT EDGAR
- Sep 14, 2026S-8 EDGAR
- Sep 14, 20268-K EDGAR
- Sep 11, 20264 PRIMARY DOCUMENT EDGAR
- Sep 10, 2026144 EDGAR
- Sep 8, 20268-K EDGAR
- Sep 8, 2026SCHEDULE 13D/A EDGAR
- Sep 3, 20264 PRIMARY DOCUMENT EDGAR
- Sep 3, 20264 PRIMARY DOCUMENT EDGAR
- Sep 3, 20264 PRIMARY DOCUMENT EDGAR
- Sep 3, 20264 PRIMARY DOCUMENT EDGAR
- Sep 1, 2026144 EDGAR
- Sep 1, 2026144 EDGAR
- Sep 1, 2026144 EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 6, 202610-Q EDGAR
- Aug 6, 20268-K EDGAR
The 628 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
122 open-market trades by officers, directors and large owners since October 2021: 8 buys and 114 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 14, 2026 | Kohl SimeonChief Executive Officer | Buy | 59,000 | $1.79 | $105.6K | Form 4 |
| Dec 5, 2025 | Landry BenjaminGeneral Counsel | Sale | 27,425 | $2.64 | $72.4K | Form 4 |
| Dec 4, 2025 | Larson-Green JulieDirector | Sale | 47,997 | $2.67 | $128.2K | Form 4 |
| Sep 5, 2025 | Landry BenjaminGeneral Counsel | Sale | 6,175 | $3.35 | $20.7K | Form 4 |
| Jun 5, 2025 | Landry BenjaminGeneral Counsel | Sale | 6,057 | $3.94 | $23.9K | Form 4 |
| May 5, 2025 | LeSueur DanielChief Operating Officer | Sale | 5,209 | $4.10 | $21.4K | Form 4 |
| Apr 3, 2025 | LeSueur DanielChief Operating Officer | Sale | 5,209 | $4.15 | $21.6K | Form 4 |
| Mar 6, 2025 | Landry BenjaminGeneral Counsel | Sale | 13,827 | $4.55 | $62.9K | Form 4 |
| Mar 5, 2025 | LeSueur DanielChief Operating Officer | Sale | 16,902 | $4.52 | $76.4K | Form 4 |
| Feb 18, 2025 | Llewelyn LindaChief People Officer | Sale | 6,441 | $5.43 | $35.0K | Form 4 |
| Feb 5, 2025 | LeSueur DanielChief Operating Officer | Sale | 5,209 | $5.76 | $30.0K | Form 4 |
| Jan 15, 2025 | Llewelyn LindaChief People Officer | Sale | 6,442 | $5.80 | $37.4K | Form 4 |
| Jan 6, 2025 | LeSueur DanielChief Operating Officer | Sale | 5,209 | $7.51 | $39.1K | Form 4 |
| Jan 6, 2025 | Landry BenjaminGeneral Counsel | Sale | 2,500 | $7.52 | $18.8K | Form 4 |
| Dec 30, 2024 | Gallagher DuncanDirector | Sale | 4,500 | $6.93 | $31.2K | Form 4 |
| Dec 23, 2024 | Gallagher DuncanDirector | Sale | 4,500 | $6.98 | $31.4K | Form 4 |
| Dec 16, 2024 | Llewelyn LindaChief People Officer | Sale | 6,442 | $7.88 | $50.8K | Form 4 |
| Dec 6, 2024 | Alger JasonChief Financial Officer | Sale | 19,599 | $8.32 | $163.1K | Form 4 |
| Dec 6, 2024 | Landry BenjaminGeneral Counsel | Sale | 19,268 | $8.32 | $160.3K | Form 4 |
| Dec 4, 2024 | LeSueur DanielChief Operating Officer | Sale | 22,773 | $7.70 | $175.4K | Form 4 |
All 122 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Palogic Value Management, L.P.SCHEDULE 13D/A, 2 filings Jun 22, 2026 to Sep 8, 202669
- Stoney Lonesome HF LPSCHEDULE 13G/A, 3 filings Dec 22, 2025 to Aug 14, 202670
- BlackRockSCHEDULE 13G/A, 5 filings Feb 3, 2022 to Jul 28, 202671
- Impax Asset Management GroupSCHEDULE 13G, 1 filing Jul 21, 202672
- Whetstone Capital Advisors, LLCSCHEDULE 13D/A, 5 filings Sep 8, 2025 to Jun 8, 202673
- VANGUARD GROUP INCSCHEDULE 13G/A, 8 filings Feb 10, 2022 to Mar 27, 202674
- First Light Asset Management, LLCSCHEDULE 13D/A, 6 filings Nov 14, 2024 to Mar 13, 202675
- Point72 Asset Management, L.P.SC 13G/A, 5 filings Nov 3, 2022 to Nov 14, 202476
- Wellington Management CompanySC 13G/A, 4 filings Feb 4, 2022 to Nov 8, 202477
- AllianceBernsteinSC 13G/A, 2 filings Feb 14, 2022 to Feb 14, 202378
- Capital Research Global InvestorsSC 13G/A, 2 filings Feb 11, 2022 to Feb 13, 202379
- MILLENNIUM MANAGEMENT LLCSC 13G/A, 2 filings Aug 30, 2022 to Jan 13, 202380
- FMR LLCSC 13G/A, 3 filings Feb 9, 2022 to Jun 10, 202281
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | Daniel BurtonChief Executive Officer | $525.0K | $4.0M82 | |
| 2025 | Benjamin AlbertChief Operating Officer and President | 53 | $343.7K | $3.0M82 |
| 2025 | Jason AlgerChief Financial Officer | 42 | $353.1K | $2.0M82 |
| 2025 | Kevin FreemanChief Commercial Officer | $395.6K | $1.8M82 | |
| 2025 | Dan LeSueurFormer Chief Operating Officer | $255.0K | $1.8M82 | |
| 2025 | Benjamin LandryGeneral Counsel | 44 | $410.0K | $1.3M82 |
| 2024 | Daniel BurtonChief Executive Officer | $525.0K | $5.5M82 | |
| 2024 | Kevin FreemanChief Commercial Officer | $387.5K | $2.2M82 | |
| 2024 | Benjamin LandryGeneral Counsel | 44 | $391.7K | $1.6M82 |
| 2024 | Jason AlgerChief Financial Officer | 42 | $338.3K | $1.3M82 |
| 2023 | Benjamin LandryGeneral Counsel | 44 | $268.4K | $946.3K82 |
| 2023 | Jason AlgerChief Financial Officer | 42 | $217.2K | $823.6K82 |
| 2023 | Kevin FreemanChief Commercial Officer | $350.0K | $644.9K82 |
Funding
Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.
- Private raises (Form D) $87.0M
Figures by year
| Year | Private raises (Form D) | Total |
|---|---|---|
| 2025 | $44.5M | $44.5M |
| 2024 | $23.0M | $23.0M |
| 2022 | $19.5M | $19.5M |
Private raises
Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.
- Jan 22, 2025Raised $44.5 million in a private offering of equity50 Form D: 109 investors so far Form D
- Nov 8, 2024Raised $18 million in a private offering of equity83 Form D: 10 investors so far Form D
- Aug 1, 2024Raised $2.5 million in a private offering of equity84 Form D: 7 investors so far Form D
- May 24, 2024Raised $2.5 million in a private offering of equity85 Form D: 13 investors so far Form D
- Apr 29, 2022Raised $6 million in a private offering of equity49 Form D: 3 investors so far Form D
- Feb 24, 2022Raised $13.5 million in a private offering of equity86 Form D: 16 investors so far Form D
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| First Light Asset Management, LLC | 12,810,861 | $25.5M | 1.5% | −67,839 |
| CDC Financial, Inc. | 7,092,698 | $14.1M | 10.8% | +785,644 |
| Palogic Value Management, L.P. | 4,922,442 | $9.8M | 3.5% | +2,025,842 |
| Impax Asset Management Group plc | 4,000,000 | $8.0M | 0.1% | +1,250,000 |
| Nepsis Inc. | 2,976,187 | $5.9M | 2.0% | +1,099,898 |
| Vanguard Capital Management LLC | 2,971,598 | $5.9M | 0.0% | +85,945 |
| BlackRock, Inc. | 1,836,373 | $3.7M | 0.0% | −3,301,649 |
| Jane Street Group, LLC | 1,037,782 | $2.1M | 0.0% | +1,011,214 |
| Dimensional Fund Advisors LP | 911,819 | $1.8M | 0.0% | −323,051 |
| Geode Capital Management, LLC | 891,357 | $1.8M | 0.0% | −610,076 |
| HighMark Wealth Management LLC | 871,082 | $1.7M | 0.6% | −32,000 |
| Caption Management, LLC | 773,650 | $1.5M | 0.1% | +1,764 |
| Mink Brook Asset Management LLC | 738,277 | $1.5M | 0.6% | New |
| Prescott Group Capital Management, L.L.C. | 710,803 | $1.4M | 0.1% | No change |
| Charles Schwab Investment Management Inc | 615,504 | $1.2M | 0.0% | +8,646 |
| Millennium Management LLC | 516,083 | $1.0M | 0.0% | New |
| Goldman Sachs Group Inc | 480,970 | $957.1K | 0.0% | +93,798 |
| Vanguard Fiduciary Trust Co | 463,005 | $921.4K | 0.0% | +19,340 |
| Citadel Advisors LLC | 453,214 | $901.9K | 0.0% | New |
| Susquehanna International Group, Llp | 437,227 | $870.1K | 0.0% | +356,073 |
| Fmr LLC | 410,637 | $817.2K | 0.0% | +43,164 |
| Hsbc Holdings PLC | 408,634 | $809.1K | 0.0% | +309,766 |
| Squarepoint Ops LLC | 400,210 | $796.4K | 0.0% | +369,772 |
| Aqr Capital Management LLC | 376,586 | $749.4K | 0.0% | −166,658 |
| State Street Corp | 360,713 | $717.8K | 0.0% | −964,136 |
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How Health Catalyst, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARHealth Catalyst, Inc.1
- CIK0001636422
- Employer ID (EIN)45-33374835
- Filer statusAccelerated filer not an emerging growth company; not a smaller reporting company; not a shell company5
- Incorporated inDelaware5
- Fiscal year endsDecember 311
- Industry code (SIC)7370 Services-Computer Programming, Data Processing, Etc.1
- SEC reviewing officeOffice of Technology, Division of Corporation Finance1
- Business address10897 South River Front Parkway, #300, South Jordan, UT 840951
- Phone801-708-68001
- Shares outstanding75,256,381 as of Jul 31, 202612
- Public float$259.0M as of Jun 30, 20255
- AuditorErnst & Young LLP, Salt Lake City, Utah PCAOB ID 42; it also attests to the company’s internal control over financial reporting5
- On EDGAR sinceMar 27, 20151
- Filings933 in all: 4 (514), 144 (149), 8-K (72), 3 (35), SC 13G/A (25), 10-Q (22), SC 13G (15), D (13)1
All 35 form types
SCHEDULE 13G/A (10), S-8 (9), 10-K (7), CORRESP (7), DEF 14A (7), DEFA14A (7), SCHEDULE 13D/A (4), UPLOAD (4), 10-K/A (3), 4/A (3), SCHEDULE 13D (3), SCHEDULE 13G (3), 424B5 (2), 5 (2), DRS/A (2), DRSLTR (2), PRE 14A (2), S-1/A (2), 424B4 (1), 8-A12B (1), 8-K/A (1), CERT (1), D/A (1), DRS (1), EFFECT (1), S-1 (1), S-3ASR (1)
- Latest filingsAnnual report (10-K) Mar 12, 2026
Quarterly report (10-Q) Aug 6, 2026
Proxy statement (DEF 14A) Jun 3, 2026
Latest 8-K (8-K) Sep 14, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock, par value $0.001 per share | HCAT | The Nasdaq Global Select Market |
From the cover page of the 10-K filed Mar 12, 2026 (Section 12(b) of the Exchange Act).5
Risk factors and legal proceedings
The risks Health Catalyst, Inc. names in Item 1A of its 10-K filed Mar 12, 2026: 64 risks under these headings, as written.5
- Risks Related to Our Business and Industry
- We operate in a highly competitive industry, and if we are not able to compete effectively, our business and results of operations will be harmed.
- Changes in the healthcare industry have and could further affect the demand for our Solution, cause our existing contracts to be terminated, and/or negatively impact the process of negotiating future contracts.
- Macroeconomic challenges (including high inflationary and/or high interest rate environments, uncertainty with tariffs, cuts in Medicaid and research funding, or market volatility and measures taken in response thereto), the tight labor market, any natural disasters or new public health crises, and regional or global conflicts (including the conflicts in the Middle East) could harm our business, results of operations, and financial condition.
- We may be unable to successfully execute on our growth initiatives, business strategies, or operating plans, as well as cost reduction and restructuring initiatives.
- If we fail to provide effective professional services and high-quality client support, our business and reputation would suffer.
- Our sales cycles can be long and unpredictable, and our sales efforts require a considerable investment of time and expense. If our sales cycle lengthens or we invest substantial resources pursuing unsuccessful sales opportunities, our results of operations and growth would be harmed.
- Our Solution may not operate properly, which could damage our reputation, give rise to claims against us, or divert application of our resources from other purposes, any of which could harm our business and results of operations.
- If we are not able to maintain and enhance our reputation and brand recognition, our business and results of operations will be harmed.
- If we do not continue to innovate and provide services that are useful to clients and users, we may not remain competitive, and our revenue and results of operations could suffer.
- Our business could be adversely affected if our clients are not satisfied with our Solution.
- If our existing clients do not continue or renew their contracts with us, renew at lower fee levels, or decline to purchase additional technology and services from us, it could have a material adverse effect on our business, financial condition, and results of operations.
The other 53 risks
- Our results of operations have in the past fluctuated and may continue to fluctuate significantly, and if we fail to meet the expectations of securities analysts or investors, our stock price and the value of an investment in our common stock could decline substantially.
- Our pricing may change over time and our ability to efficiently price our Solution will affect our results of operations and our ability to attract or retain clients.
- If our Solution fails to provide accurate and timely information, or if our content or any other element of our Solution is associated with faulty clinical decisions or treatment, we could have liability to clients, clinicians, patients, or others, which could adversely affect our results of operations.
- Our increasing reliance on AI and machine learning technologies may expose us to significant risks, including development and deployment challenges, regulatory uncertainties, and potential third-party claims, which could adversely affect our reputation, business, results of operations, and financial condition.
- Future litigation against us could be costly and time-consuming to defend and could result in additional liabilities.
- We derive a significant portion of our revenue from our largest clients. The loss, termination, or renegotiation of any contract could negatively impact our results.
- Because we generally recognize technology and professional services revenue ratably over the term of the contract for our services, a significant downturn in our business may not be reflected immediately in our results of operations, which increases the difficulty of evaluating our future financial performance.
- If we are unable to implement and maintain effective internal controls over financial reporting, investors may lose confidence
- in the accuracy and completeness of our financial reports and the market price of our common stock could be adversely affected.
- We may acquire other companies or technologies, which could divert our management’s attention, result in dilution to our stockholders, and otherwise disrupt our operations and we may have difficulty integrating any such acquisitions successfully or realizing the anticipated benefits therefrom, any of which could have an adverse effect on our business, financial condition, and results of operations.
- Because competition for our target employees is intense, we may not be able to attract and retain the highly skilled employees we need to support our continued growth.
- We depend on our senior management team, and the loss of one or more of our executive officers or key employees or an inability to attract and retain highly skilled employees could adversely affect our business.
- Our corporate culture has contributed to our success, and if we cannot maintain this culture as we grow, we could lose the innovation, creativity, and teamwork fostered by our culture, which could harm our business.
- If we fail to effectively manage our growth and organizational change, our business and results of operations could be harmed.
- We may not grow at the rates we historically have achieved or at all, even if our key metrics may indicate growth.
- Our estimates of market opportunity and forecasts of market growth may prove to be inaccurate, and even if the markets in which we compete achieve the forecasted growth, our business may not grow at similar rates, or at all.
- Risks Related to Data and Intellectual Property
- Failure by our clients to obtain proper permissions and waivers may result in claims against us or may limit or prevent our use of data, which could harm our business.
- Our business and operations may suffer in the event of information technology system failures, cyberattacks, or deficiencies in our cybersecurity.
- Our Solution is dependent on our ability to source data from third parties, and such third parties could take steps to block our access to data, or increase fees or impose fees for such access, which could impair our ability to provide our Solution, limit the effectiveness of our Solution or adversely affect our financial condition and results of operations.
- We rely on third-party providers, including Microsoft Azure, for computing infrastructure, network connectivity, and other technology-related services needed to deliver our Solution. Any disruption in the services provided by such third-party providers could adversely affect our business and subject us to liability.
- We rely on Internet infrastructure, bandwidth providers, data center providers, other third parties, and our own systems for providing our Solution to our users, and any failure or interruption in the services provided by these third parties or our own systems could expose us to litigation, potentially require us to issue credits to our clients, and negatively impact our relationships with users or clients, adversely affecting our brand and our business.
- Our business could be adversely impacted by changes in laws and regulations related to the Internet or changes in access to the Internet generally.
- Our Solution utilizes open-source software, and any failure to comply with the terms of one or more of these open-source licenses could adversely affect our business.
- We employ third-party licensed software and software components for use in or with our Solution, and the inability to maintain these licenses or the presence of errors in the software we license could limit the functionality of our Solution and result in increased costs or reduced service levels, which would adversely affect our business.
- Any failure to protect our intellectual property rights could impair our ability to protect our proprietary technology and our brand.
- We may be sued by third parties for alleged infringement of their proprietary rights or misappropriation of intellectual property.
- Risks Related to Governmental Regulation
- Risks Related to Healthcare and Data Privacy and Security Regulation
- Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could adversely affect our business, results of operations, and financial condition.
- Government regulation of healthcare creates risks and challenges with respect to our compliance efforts and our business strategies.
- If our arrangements with clinicians and other healthcare professionals are found to constitute the improper rendering of professional medical services or fee splitting under applicable state laws, our business, financial condition, and our ability to operate in those states could be adversely impacted.
- The FDA may modify its enforcement policies with respect to medical software products, and our software products may become subject to extensive regulatory requirements, which may increase the cost of conducting, or otherwise harm, our business.
- The healthcare regulatory and political framework is uncertain and evolving.
- Due to the particular nature of certain services we provide or the manner in which we provide them, we may be subject to additional government regulation and foreign government regulation.
- Risks Related to Tax Regulation
- Taxing authorities may successfully assert that we should have collected or in the future should collect sales and use, value-added or similar transactional taxes, and we could be subject to liability with respect to past or future sales, which could adversely affect our results of operations.
- Unanticipated changes in our effective tax rate and additional tax liabilities, including as a result of our international operations or implementation of new tax rules, could harm our future results.
- Our ability to use our net operating losses to offset future taxable income may be subject to certain limitations.
- Comprehensive tax reform legislation could adversely affect our business and financial condition.
- Risks Related to Our Indebtedness
- Our indebtedness could adversely affect our financial condition and prevent us from fulfilling our existing or future debt obligations, and we may not generate sufficient cash flow from our business to pay our debt.
- Our Credit Agreement contains covenants and other provisions that restrict our ability to take certain actions and may limit our ability to operate or grow our business in the future.
- We are exposed to interest rate risks with regard to our Term Loan Facility and any future refinancing thereof.
- Risks Related to an Investment in Our Securities
- We have experienced significant net losses since inception, we expect to incur losses in the future, and we may not be able to generate sufficient revenue to achieve and maintain profitability.
- We have a relatively limited operating history in an evolving industry which makes it difficult to evaluate our current business future prospects and increases the risk of your investment.
- The market price of our common stock has decreased in recent periods, may be volatile, and may further decline for many reasons, including reasons that are not related to our operating performance, and you may lose all or part of your investments.
- If securities or industry analysts do not continue to publish research, or publish inaccurate or unfavorable research, about our business, the price of our common stock and trading volume could decline.
- We cannot guarantee that the Share Repurchase Plan will be fully consummated or will enhance stockholder value, and share repurchases could affect the price of our common stock.
- Our issuance of additional capital stock in connection with financings, acquisitions, investments, our stock incentive plans, or otherwise will dilute all other stockholders.
- The requirements of being a public company may strain our resources, divert management’s attention, and affect our ability to attract and retain executive management and qualified board members.
- We do not intend to pay dividends on our common stock and, consequently, the ability of common stockholders to achieve a return on investment will depend on appreciation, if any, in the price of our common stock.
- We could be subject to securities class action litigation.
- Risks Related to Our Charter and Bylaws
- Provisions in our charter documents and under Delaware law could make an acquisition of our company more difficult, limit attempts by our stockholders to replace or remove our current board of directors, and limit the market price of our common stock.
- Our amended and restated bylaws designate a state or federal court located within the State of Delaware as the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit stockholders’ ability to obtain a favorable judicial forum for disputes with us.
- General Risks
- Changes in accounting principles may cause previously unanticipated fluctuations in our financial results, and the implementation of such changes may impact our ability to meet our financial reporting obligations.
- Economic uncertainties or downturns in the general economy or the industries in which our clients operate could disproportionately affect the demand for our Solution and negatively impact our results of operations.
- Investors’ expectations of our performance relating to environmental, social, and governance factors may impose additional costs and expose us to new risks.
Legal proceedings
We are, and from time to time may be, party to litigation and subject to claims incident to the ordinary course of business. As our growth continues, we may become party to an increasing number of litigation matters and claims. The outcome of litigation and claims cannot be predicted with certainty, and the resolution of these matters could materially affect our future results of operations, cash flows, or financial position. We are not presently party to any other legal proceedings that in the opinion of management, if determined to adversely affect us, may individually or taken together have a material adverse effect on our business, operating results, financial condition, or cash flows.
For information regarding a recent legal proceeding that was dismissed with prejudice on June 20, 2023, refer to Note 16— “Contingencies” to the Consolidated Financial Statements in Item 8, which is incorporated herein by reference.
The opening of Item 3, Legal Proceedings.5
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15SEC EDGARSimeon Kohl, Chief executive officer
- 16
- 17SEC EDGARBenjamin Albert, President
- 18SEC EDGARJames Patrick Nelli Jr., President
- 19SEC EDGARJason Alger, Chief financial officer
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30SEC EDGARLinda Llewelyn, Chief People Officer
- 31SEC EDGARSteven H. Nelson, Board member
- 32SEC EDGARJustin Spencer, Board member
- 33SEC EDGARMathew Paul Arens, Board member
- 34SEC EDGARGreen Jill Hoggard, Board member
- 35SEC EDGARMatthew Kolb, Board member
- 36SEC EDGARDawn Smith, Board member
- 37SEC EDGARJulie Larson-Green, Board member
- 38SEC EDGARMark B. Templeton, Board member
- 39SEC EDGARAnita Pramoda, Board member
- 40SEC EDGARD. Fraser Bullock, Board member
- 41SEC EDGARDuncan Gallagher, Board member
- 42SEC EDGARJohn A. Kane, Board member
- 43SEC EDGARMichael Edward Dixon, Board member
- 44SEC EDGARPromod Haque, Board member
- 45SEC EDGARTimothy G. Ferris, Board member
- 46SEC EDGARTodd C. Cozzens, Board member
- 47SEC EDGARBenjamin Landry, General counsel
- 48SEC EDGARDaniel H. Orenstein, General counsel
- 49
- 50
- 51
- 52
- 53
- 54SEC EDGARShareholder vote
- 55
- 56SEC EDGARResults of operations
- 57
- 58
- 59SEC EDGARExecutive or director change
- 60SEC EDGARResults of operations
- 61
- 62SEC EDGARExecutive or director change
- 63NasdaqNasdaq calendar
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86